Jiangsu Recbio Technology Co (FRA:G93) LT-Debt-to-Total-Asset : 0.23 (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Jiangsu Recbio Technology Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Jiangsu Recbio Technology Co's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.23.

Jiangsu Recbio Technology Co's long-term debt to total assets ratio increased from Jun. 2023 (0.23) to Jun. 2024 (0.23). It may suggest that Jiangsu Recbio Technology Co is progressively becoming more dependent on debt to grow their business.

Jiangsu Recbio Technology Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Jiangsu Recbio Technology Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Recbio Technology Co LT-Debt-to-Total-Asset Chart

Jiangsu Recbio Technology Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.04

0.11

0.27

0.20

Jiangsu Recbio Technology Co Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial					0.11	0.23	0.27	0.23	0.20

Jiangsu Recbio Technology Co LT-Debt-to-Total-Asset Calculation

Jiangsu Recbio Technology Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	75.741	/	280.779
	=

Jiangsu Recbio Technology Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	60.114	/	263.629
	=

Jiangsu Recbio Technology Co (FRA:G93) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Jiangsu Recbio Technology Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Jiangsu Recbio Technology Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Jiangsu Recbio Technology Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jiangsu Recbio Technology Co Ltd (FRA:G93) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

02179:Hong Kong

Address

No. 888 Yaocheng Avenue, Medical High-tech District, Jiangsu Province, Taizhou, CHN

Website

https://www.recbio.cn

Jiangsu Recbio Technology Co Ltd is a vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. The company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.

Jiangsu Recbio Technology Co Headlines

No Headlines